Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicine.
Under the agreement, Closed Loop Medicine – a TechBio company – and Teva UK, a pharmaceutical company, will investigate opportunities to utilise Closed Loop Medicine’s proprietary software as a medical device (SaMD) technology platform.
The platform aims to advance the development of personalised medicines, as well as improve drug efficacy and outcomes in patients with specific chronic disorders by combining dose-optimised drug therapy with digital care.
Dr Paul Goldsmith, Chief Medical Officer and Innovation Officer, Co-Founder and President of Closed Loop Medicine, said: “As clinicians, we know that dosing of drugs is a huge problem. In the most extreme cases, we are seeing patients having severe adverse events, for example when required to change dose levels to undergo surgery. Being able to predict personalised dose levels could be transformational."
Hypertension product CLM-HT01 has demonstrated the technology’s ability to dose optimise drug therapy and minimise side effects
This strategic partnership harnesses Closed Loop Medicine’s proprietary SaMD and combines it with Teva’s pharmaceutical products creating the opportunity for digital companions to be prescribed alongside traditional therapeutics, enabling real-world data integration and improved effectiveness of innovative and known medicines.
Recent clinical trial results for a hypertension product, CLM-HT01, have demonstrated the technology’s ability to dose optimise drug therapy and minimise side effects whilst achieving blood pressure control, with exceptionally high medication adherence.1
Personalised medicine is an aspiration of the modern healthcare system, yet existing medicines are typically prescribed based on their average effects in a population and rarely dose optimised for the individual.
This “one size fits all” approach results in increased side effects and adverse reactions, medication non-adherence and consequently poorer patient outcomes and higher healthcare costs.
For example, the annual cost of drug-related morbidity and mortality resulting from non-optimised medication was estimated at $528.4 billion in the US, in 2016,2 and the projected annual cost of adverse drug reactions alone to the NHS is £2.21 billion.3
Kim Innes, Teva’s General Manager, UK & Ireland, said: “We are excited to be working with Closed Loop Medicine, who have demonstrated themselves to be compelling innovators in the area of personalised medicine. We know that the patient experience can sometimes be less than optimal and as the largest supplier of medicines to the NHS, the potential to combine ‘drug’ & ‘digital’ could create significant improvements to lives of patients at great scale. We are very excited about the future of this partnership.”
References
- Collier DJ, et al. Personalized Antihypertensive Treatment Optimization With Smartphone-Enabled Remote Precision Dosing of Amlodipine During the COVID-19 Pandemic (PERSONAL-CovidBP Trial). 2024 https://www.ahajournals.org/doi/10.1161/JAHA.123.030749 [accessed February 2024]
- Watanabe JH, et al. Cost of prescription drug–related morbidity and mortality. Annals of Pharmacotherapy. 2018;52(9):829-837
- Osanlou R, et al. Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions. BMJ Open. 2022;12(7):e055551
